We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (30)
- Cosmetics (4)
- COVID-19 (11)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (41)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (5)
- Weight loss products (1)
Search
292 result(s) found, displaying 126 to 150
-
GuidanceGuidance on requirements for Australian market authorisation of a cough expectorant containing guaifenesin, for an OTC new medicine N2 application.
-
GuidanceGuidance on specific criteria and paperwork required for submission to the TGA to ensure conformance with TGO 93.
-
GuidanceGuidance on how to prepare your application for orphan drug designation so that it meets eligibility criteria and requirements.
-
GuidanceGuidance for sponsors of faecal microbiota transplant (FMT) products, which are regulated as biologicals.
-
GuidanceGuidance to assist Australian corporations seeking to apply for an Australian conformity assessment body (CAB) determination for medical devices (including IVDs) by the TGA.
-
GuidanceGuidance about the process of applying for a priority determination, which is the first step of the priority review registration pathway.
-
GuidanceGuidance on the information that we include in AusPARS for prescription medicines and when we publish them.
-
GuidanceGuidance for the deletion of commercially confidential and personal information in an Australian Public Assessment Report (AusPAR).
-
GuidanceThis guidance is to assist sponsors understand their requirements when supplying ‘unapproved’ therapeutic goods under the Special Access Scheme and Authorised Prescriber Pathway.
-
GuidanceGuidance to help determine whether products are separate and distinct biologicals that will need to be included as separate ARTG entries.
-
GuidanceGuidance to explain what we need for software and apps that work with COVID-19 rapid antigen tests.
-
GuidanceThis guidance will assist you in determining if a product is a cosmetic or a therapeutic good and how to comply with Australian regulatory requirements and advertising rules for therapeutic goods.
-
GuidanceGuidance on declaring and managing conflicts of interest and confidentiality obligations for TGA advisory committee members.
-
GuidanceAn overview on the application process for manufacturers aiming to obtain a TGA-issued conformity assessment certificate.
-
GuidanceGuidance on TGO 107: Mandatory labelling requirements for biologicals and human cell and tissue materials.
-
GuidanceGuidance for notifying the TGA about substantial changes to, or transfers of, conformity assessment certificates.
-
GuidanceGuidance on applying for a provisional determination, which is the first step of the provisional approval pathway.
-
GuidanceThis guidance explains parts 4 and 5 of the Code, which requires certain information to be prominently displayed or communicated in advertisements for therapeutic goods.
-
GuidanceGuidance on the legislative, regulatory and good clinical practice requirements when conducting clinical trials in Australia using unapproved therapeutic goods.
-
GuidanceGuidance to help work out if your autologous HCT product is exempt from some aspects of our regulation.
-
GuidanceThis guidance explains parts 2 and 3 of the Code, which requires advertising about therapeutic goods to be accurate, balanced, safe and not misleading.
-
GuidanceGuidance to help work out if your autologous HCT product is excluded from our regulation.
-
GuidanceThis guidance explains part 7 of the Code, which outlines rules for using samples and incentives when advertising therapeutic goods.
-
GuidanceThis Guidance explains part 8 of the Code, which outlines rules for making restricted representations when advertising therapeutic goods.
-
GuidanceThis Guidance explains part 9 of the Code, which has requirements about advertising the price of prescription medicines and certain pharmacist-only medicines to the public.